---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001352"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:54:08.151902+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aligos Q4 net loss $82.2M; cash $56.9M; ALG-000184 Phase 2 mid-2025

## Summary
- Q4 net loss $82.2M ($13.08/share) vs $27.9M ($5.50) in Q4 2023; full-year net loss $131.2M vs $87.7M.
- Cash & investments $56.9M at Dec 31, 2024; $105M private placement closed Feb 2025 extends runway into H2 2026.
- Lead CAM-E candidate ALG-000184 Phase 2 expected to start mid-2025; 96-week data to be presented in 2025.
- THR-β agonist ALG-055009 for MASH showed up to 46.2% placebo-adjusted median relative liver fat reduction at Week 12.
- Lesley Ann Calhoun promoted to EVP, COO and CFO.

## SEC filing metadata
- accession: 0001171843-25-001352
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184325001352/0001171843-25-001352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184325001352/f8k_031025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001352
- JSON: https://secwatch.observer/filing/0001171843-25-001352.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.